A rare case of bladder cancer that metastasized to brain, heart, and lung lymph nodes benefited from immunotherapy

World Journal of Surgical Oncology

Case Report

Hua-jun Zhang¹  Hong-yao Liu¹  Zhong-jian Li¹  Jin-tao Chen¹  Lian-kai Zhu¹  Zhi-bo Wang¹  Xu-wei Zhao¹ 

[1] Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, 030032, Taiyuan, China;

关键词: Bladder cancer;    Brain metastasis;    Heart metastasis;    Immunotherapy;    Tislelizumab;   

DOI  :  10.1186/s12957-022-02876-9

 received in 2022-08-30, accepted in 2022-12-09,  发布年份 2022

来源: Springer

【 摘 要 】

Bladder cancer is a common malignant tumor of the genitourinary system, with the primary cause of death being metastasis. The most common metastatic sites are the lymph nodes, liver, lung, bone, peritoneum, pleura, kidney, adrenal gland, and the intestine. Brain and heart metastases are rare. In this report, we describe a patient who had pulmonary lymph node metastases more than a year after being diagnosed with bladder cancer, followed by brain and cardiac metastases more than two years later. Following the failure of standard first-line chemotherapy, the patient accepted 6 cycles of tislelizumab immunotherapy. The re-examination revealed that the bilateral frontal brain metastases had vanished, the right temporal lobe metastases had been greatly decreased, the neurological symptoms had been alleviated, and the cardiac metastases had disappeared. This is a rare clinical case with encouraging effects of tislelizumab and can serve as a model for the treatment of similar patients.

【 授权许可】

CC BY   
© The Author(s) 2022

【 图 表 】

12951_2022_1749_Article_IEq1.gif

Fig. 4

Fig. 2

Fig. 3

Fig. 1